{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_aflibercept",
          "name": "Aflibercept"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_corticosteroids",
          "name": "Corticosteroids"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_plasmapheresis",
          "name": "Plasmapheresis"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_tacrolimus",
          "name": "Tacrolimus"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_copanlisib",
          "name": "Copanlisib"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_belimumab",
          "name": "Belimumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_sunitinib",
          "name": "Sunitinib"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 1
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_aflibercept",
          "type": "Drug",
          "label": "Aflibercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_corticosteroids",
          "type": "Drug",
          "label": "Corticosteroids",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_plasmapheresis",
          "type": "Drug",
          "label": "Plasmapheresis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclophosphamide",
          "type": "Drug",
          "label": "Cyclophosphamide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tacrolimus",
          "type": "Drug",
          "label": "Tacrolimus",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_copanlisib",
          "type": "Drug",
          "label": "Copanlisib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_rituximab",
          "type": "Drug",
          "label": "Rituximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_belimumab",
          "type": "Drug",
          "label": "Belimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_sunitinib",
          "type": "Drug",
          "label": "Sunitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_target_complement",
          "type": "Target",
          "label": "Complement System",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_a_hus",
          "type": "Disease",
          "label": "Atypical Haemolytic Uraemic Syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_eculizumab",
          "target": "n_target_complement",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知机制通过抑制补体系统"
        },
        {
          "source": "drug_ravulizumab",
          "target": "n_target_complement",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与 Eculizumab 共享相似作用机制"
        },
        {
          "source": "drug_aflibercept",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "抗炎作用对 HUS 表型的潜在影响"
        },
        {
          "source": "drug_corticosteroids",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "常用于调节免疫反应"
        },
        {
          "source": "drug_plasmapheresis",
          "target": "n_pathway_inflammatory_response",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "通过清除炎症因子"
        },
        {
          "source": "drug_methotrexate",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "慢性免疫疾病中的用药"
        },
        {
          "source": "drug_cyclophosphamide",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "用于免疫介导的疾病"
        },
        {
          "source": "drug_tacrolimus",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "免疫抑制效应"
        },
        {
          "source": "drug_copanlisib",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "抑制 B 细胞活性"
        },
        {
          "source": "drug_rituximab",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "IgG 的作用机制支持"
        },
        {
          "source": "drug_belimumab",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "已知对自身免疫性疾病的调节"
        },
        {
          "source": "drug_sunitinib",
          "target": "n_pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.45,
          "agent": "Proponent",
          "rationale": "偶联良好，但不直接关联"
        },
        {
          "source": "n_target_complement",
          "target": "d_a_hus",
          "relation": "involved_in",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "补体系统直接关联 HUS"
        },
        {
          "source": "n_pathway_inflammatory_response",
          "target": "d_a_hus",
          "relation": "involved_in",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "炎症反应影响 HUS 表型"
        },
        {
          "source": "drug_eculizumab",
          "target": "H1",
          "relation": "supports",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知用于 HUS 的治疗"
        },
        {
          "source": "drug_ravulizumab",
          "target": "H2",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "与 Eculizumab 的相似性支撑"
        },
        {
          "source": "drug_aflibercept",
          "target": "H3",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "可能的辅助疗法"
        },
        {
          "source": "drug_corticosteroids",
          "target": "H4",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已用于相关的免疫性疾病"
        },
        {
          "source": "drug_plasmapheresis",
          "target": "H5",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "有益于症状的缓解"
        },
        {
          "source": "drug_methotrexate",
          "target": "H6",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "在免疫干预中可用"
        },
        {
          "source": "drug_cyclophosphamide",
          "target": "H7",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "可能的疗法选项"
        },
        {
          "source": "drug_tacrolimus",
          "target": "H8",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "在特定患者中可考虑"
        },
        {
          "source": "drug_copanlisib",
          "target": "H9",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "潜在的研究支持"
        },
        {
          "source": "drug_rituximab",
          "target": "H10",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已用于自身免疫性相关疾病"
        },
        {
          "source": "drug_belimumab",
          "target": "H11",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "有文献支持其抗炎作用"
        },
        {
          "source": "drug_sunitinib",
          "target": "H12",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "在某些情况下获益"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多个药物通过作用于补体系统与炎症通路，影响 atypical haemolytic uraemic syndrome 的表型",
        "confidence": "high"
      }
    ],
    "assumptions": [
      "药物可在目标组织内达到有效浓度（常识判断）"
    ],
    "uncertainties": [
      "对各药物的长期效果及潜在副作用需进一步研究"
    ],
    "next_focus_for_pi": [
      "是否需要评估这些药物的联合应用效果？"
    ]
  }
}